Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pIRF7 GPC3-targeted CAR T cells
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
pIRF7 GPC3-targeted CAR T cells are an investigational cell therapy designed to treat Glypican-3 (GPC3) expressing solid tumors, specifically hepatocellular carcinoma (HCC) and hepatoblastoma (HBL). This next-generation CAR T-cell product incorporates a constitutively active (phosphorylated) form of Interferon Regulatory Factor 7 (pIRF7) to enhance antitumor activity. IRF7 was identified as a key transcriptional driver associated with therapeutic response in patients treated with earlier iterations of GPC3-CAR T cells. The addition of pIRF7 is intended to promote a more favorable T-cell phenotype (higher naïve and central memory populations), increase expansion, and improve killing efficacy and persistence within the immunosuppressive tumor microenvironment of solid tumors.
- Other names
- Phosphorylated IRF7 GPC3-targeted CAR T cellspIRF7-expressing GPC3-CAR T cellspIRF-7-expressing GPC3-CAR T cellspIRF 7-expressing GPC3-CAR T cells
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on pIRF7 GPC3-targeted CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pIRF7 GPC3-targeted CAR T cells.